Anebulo Pharmaceuticals (ANEB)
OTHER OTC:ANEB
Top Page
Anebulo Pharmaceuticals
(OTC:ANEB)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.51
▼(-54.60% Downside)
Action:ReiteratedDate:04/07/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn) and a major negative corporate event (planned Nasdaq delisting/SEC deregistration). Technicals also reflect a broader downtrend, while valuation signals are limited due to negative earnings and no dividend support.
Positive Factors
Balance-sheet strength
Zero debt and positive equity provide structural solvency and lower refinancing risk, giving management runway to fund clinical activities. This reduces interest burden and preserves optionality for strategic financing or partnerships over the next several quarters.
Negative Factors
Pre-revenue, persistent losses
The company is pre-revenue and generates recurring net losses, limiting internal funding for development. Persistent negative results necessitate external financing or partnerships, creating dilution risk and constraining long-term investment capacity absent clinical or licensing milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet strength
Zero debt and positive equity provide structural solvency and lower refinancing risk, giving management runway to fund clinical activities. This reduces interest burden and preserves optionality for strategic financing or partnerships over the next several quarters.
Read all positive factors
Anebulo Pharmaceuticals (ANEB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$21.93M
Dividend YieldN/A
Average Volume (3M)16.98K
Price to Earnings (P/E)―
Beta (1Y)0.27
Revenue GrowthN/A
EPS Growth23.10%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding40,784,733
10 Day Avg. Volume7,376
30 Day Avg. Volume16,982
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)4.18
Price to Sales (P/S)0.00
P/FCF Ratio-7.67
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.37
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Anebulo Pharmaceuticals Business Overview & Revenue Model
Company Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a...
How the Company Makes Money
null...
Anebulo Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -8.32M | -8.10M | -7.79M | -11.73M | -6.83M | -30.24M |
| Net Income | -7.98M | -8.48M | -8.20M | -11.73M | -6.83M | -30.25M |
Balance Sheet | ||||||
| Total Assets | 9.42M | 12.15M | 4.07M | 11.67M | 15.58M | 21.65M |
| Cash, Cash Equivalents and Short-Term Investments | 9.04M | 11.63M | 3.09M | 11.25M | 14.55M | 19.99M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.49M | 487.69K | 260.58K | 1.07M | 512.53K | 241.63K |
| Stockholders Equity | 7.94M | 11.66M | 3.81M | 10.60M | 15.07M | 21.41M |
Cash Flow | ||||||
| Free Cash Flow | -5.84M | -6.35M | -8.09M | -9.68M | -5.44M | -4.87M |
| Operating Cash Flow | -5.84M | -6.35M | -8.09M | -9.68M | -5.44M | -4.87M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | -116.66K | 14.88M | -62.35K | 6.38M | 0.00 | 21.83M |
Anebulo Pharmaceuticals Technical Analysis
Negative
1.13
Price Trends
0.66
Negative
1.18
Negative
1.78
Negative
Market Momentum
-0.02
Positive
37.35
Neutral
4.15
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANEB, the sentiment is Negative. The current price of 1.13 is above the 20-day moving average (MA) of 0.84, above the 50-day MA of 0.66, and below the 200-day MA of 1.78, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 37.35 is Neutral, neither overbought nor oversold. The STOCH value of 4.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANEB.
Anebulo Pharmaceuticals Risk Analysis
Anebulo Pharmaceuticals disclosed 49 risk factors in its most recent earnings report. Anebulo Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Anebulo Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $727.72M | -8.12 | -45.01% | ― | ― | -7.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $228.78M | -3.87 | -47.04% | ― | ― | 69.30% | |
49 Neutral | $71.55M | -8.24 | 26.10% | ― | ― | ― | |
47 Neutral | $323.93M | -0.70 | ― | ― | -63.96% | -28.50% | |
45 Neutral | $22.20M | -0.37 | ― | ― | -33.00% | 54.91% | |
41 Neutral | $21.93M | -5.19 | -74.58% | ― | ― | 23.10% |
* Healthcare Sector Average
ANEB
Anebulo Pharmaceuticals
0.50
-0.45
-47.37%
VTGN
VistaGen Therapeutics
0.58
-1.65
-74.17%
BYSI
Beyondspring
1.75
0.58
49.57%
SRZN
Surrozen
29.86
20.37
214.65%
CNTX
Context Therapeutics
2.46
1.61
188.06%
ANRO
Alto Neuroscience, Inc.
25.75
23.67
1137.98%
Anebulo Pharmaceuticals Corporate Events
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Anebulo Pharmaceuticals Announces Voluntary Nasdaq Delisting Plan
Negative
Feb 6, 2026
On February 5, 2026, Anebulo Pharmaceuticals’ board approved the voluntary delisting of the company’s common stock from the Nasdaq Capital Market and the subsequent deregistration of its shares with the U.S. Securities and Exchange Com...
Stock Buyback
Anebulo Pharmaceuticals Completes Oversubscribed Share Repurchase Tender
Positive
Jan 29, 2026
On January 29, 2026, Anebulo Pharmaceuticals reported the final results of its voluntary self-tender offer, which expired on January 26, 2026, to repurchase up to 300,000 shares of common stock at $3.50 per share. The offer was heavily oversubscri...
Business Operations and StrategyStock Buyback
Anebulo Pharmaceuticals Announces Oversubscribed Self-Tender Offer Results
Positive
Jan 27, 2026
On January 27, 2026, Anebulo Pharmaceuticals reported preliminary results from its voluntary self-tender offer for up to 300,000 shares of its common stock at $3.50 per share in cash, following the offer’s expiration on January 26, 2026. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.